[
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For June 2025",
    "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
    "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748384108,
      "headline": "Best Dividend Aristocrats For June 2025",
      "id": 134736842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2173105185/image_2173105185.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
      "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Reports for Coca-Cola, Abbott & AT&T",
    "summary": "Coca-Cola, Abbott, and AT&T beat peers YTD with strong earnings, innovation, and strategic moves, but face headwinds from FX, costs, and competition.",
    "url": "https://finnhub.io/api/news?id=2c9a3e6b15e21bb51cd2e9f2c01d2947ac3ca0a0ce6ee61e75aca3df96bd5ebe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748377260,
      "headline": "Top Stock Reports for Coca-Cola, Abbott & AT&T",
      "id": 134741982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Coca-Cola, Abbott, and AT&T beat peers YTD with strong earnings, innovation, and strategic moves, but face headwinds from FX, costs, and competition.",
      "url": "https://finnhub.io/api/news?id=2c9a3e6b15e21bb51cd2e9f2c01d2947ac3ca0a0ce6ee61e75aca3df96bd5ebe"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock rises Tuesday, still underperforms market",
    "summary": "Abbott Laboratories stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=e93ffa94efd31435466bd183ee76a723de5a0313cdbff37214743d766fa06924",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748363640,
      "headline": "Abbott Laboratories stock rises Tuesday, still underperforms market",
      "id": 134718260,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=e93ffa94efd31435466bd183ee76a723de5a0313cdbff37214743d766fa06924"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery",
    "summary": "Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease. This life-changing therapy is available for patients whose mitral valves are not functioning properly due to severe mitral annular calcification (MAC), a buildup of calcium within the ring-like structure (known as an annulus) that supports the mitral valve.",
    "url": "https://finnhub.io/api/news?id=1b61f97e381ece3fba0e23042bad11d55890e62ecc510d854af6b8eee3d6d28c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748350800,
      "headline": "Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery",
      "id": 134716061,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease. This life-changing therapy is available for patients whose mitral valves are not functioning properly due to severe mitral annular calcification (MAC), a buildup of calcium within the ring-like structure (known as an annulus) that supports the mitral valve.",
      "url": "https://finnhub.io/api/news?id=1b61f97e381ece3fba0e23042bad11d55890e62ecc510d854af6b8eee3d6d28c"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Receives FDA Approval for Tendyne??, First-Of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery",
    "summary": "Abbott announced the U.S. Food and Drug Administration has approved the company's Tendyne?? transcatheter mitral valve replacement system to treat people with mitral valve disease. This...",
    "url": "https://finnhub.io/api/news?id=8c5d4328da8616e8da6eed60d72fc2d2dcb9a99427e861b751fa0cebc9fa3874",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748346652,
      "headline": "Abbott Receives FDA Approval for Tendyne??, First-Of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery",
      "id": 134709420,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott announced the U.S. Food and Drug Administration has approved the company's Tendyne?? transcatheter mitral valve replacement system to treat people with mitral valve disease. This...",
      "url": "https://finnhub.io/api/news?id=8c5d4328da8616e8da6eed60d72fc2d2dcb9a99427e861b751fa0cebc9fa3874"
    }
  },
  {
    "ts": null,
    "headline": "A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)",
    "summary": "Key Insights Abbott Laboratories' estimated fair value is US$125 based on 2 Stage Free Cash Flow to Equity With US$131...",
    "url": "https://finnhub.io/api/news?id=f0f1b2b76bba351ab0c32d1cb628bb4677451ef5ceaa3779dc607669714d9dcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748343665,
      "headline": "A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)",
      "id": 134716063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Key Insights Abbott Laboratories' estimated fair value is US$125 based on 2 Stage Free Cash Flow to Equity With US$131...",
      "url": "https://finnhub.io/api/news?id=f0f1b2b76bba351ab0c32d1cb628bb4677451ef5ceaa3779dc607669714d9dcb"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story",
    "summary": "Abbott's steady cash flow, premium margins, and expanding diabetes and medtech franchises make it a long-term winner. See why ABT stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=cf4df8e3bd73e3166e3c62e9dc8e85b316e9d2e22184a74643b0d315246f2164",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748322551,
      "headline": "Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story",
      "id": 134706918,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325784605/image_1325784605.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbott's steady cash flow, premium margins, and expanding diabetes and medtech franchises make it a long-term winner. See why ABT stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=cf4df8e3bd73e3166e3c62e9dc8e85b316e9d2e22184a74643b0d315246f2164"
    }
  },
  {
    "ts": null,
    "headline": "BNY Mellon Worldwide Growth Fund, Inc. Q1 2025 Commentary",
    "summary": "BNY Mellon Worldwide Growth Fund, Inc. Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=d747f4425bb8b892edc09c7853339bc8b4919a4193632e2818c759da21de7bbd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748321160,
      "headline": "BNY Mellon Worldwide Growth Fund, Inc. Q1 2025 Commentary",
      "id": 134706770,
      "image": "",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=d747f4425bb8b892edc09c7853339bc8b4919a4193632e2818c759da21de7bbd"
    }
  }
]